The global biosimilars market is projected to grow from USD 35.04 billion in 2025 to USD 72.29 billion by 2035, registering a CAGR of 7.5% during the forecast period, according to a new market research report published by MarketsandMarkets™.
The study highlights how increasing biologics demand, rising healthcare cost pressures, and the growing number of biologic patent expirations are reshaping the competitive pharmaceutical landscape worldwide. The market was valued at USD 32.75 billion in 2024, reflecting continued commercial adoption of biosimilar therapies across oncology, immunology, diabetes, and autoimmune disease applications.
Access key market insights and highlights from the report
brochure:
Download
Report Brochure
As healthcare systems continue to prioritize treatment affordability and wider patient access, biosimilars are emerging as a strategic focus area for pharmaceutical manufacturers, payers, healthcare providers, and regulatory agencies globally.
The report identifies several major growth drivers accelerating market expansion:
- Increasing approvals for biosimilar products across major regions
- Patent expiry of blockbuster biologics
- Rising prevalence of chronic and autoimmune diseases
- Expanding physician confidence in biosimilar therapies
- Growing focus on reducing biologics treatment costs
- Advancements in biologics manufacturing technologies
- Increasing investments in biosimilar development pipelines
According to the study, monoclonal antibodies (mAbs) continue to account for a significant share of the biosimilars landscape due to strong adoption across oncology and inflammatory disease treatments. The report further evaluates market performance across recombinant hormones, immunomodulators, anti-inflammatory agents, and other therapeutic classes.
The analysis provides detailed segmentation across:
- Product type
- Application
- Manufacturing type
- Indication
- Route of administration
- Distribution channel
- End user
- Region
The report also delivers extensive coverage of the competitive ecosystem, including company benchmarking, product portfolio analysis, strategic developments, pricing analysis, and pipeline assessments.
Key Strategic Insights Covered in the Report
- Market size estimates and forecasts through 2035
- Regional revenue analysis
- Biosimilar pipeline analysis
- Regulatory scenario assessment
- Pricing trends and reimbursement analysis
- Patent landscape evaluation
- AI and Gen AI impact assessment on biosimilar commercialization
- Market share analysis of leading companies
- Clinical development trends
- Commercialization strategies adopted by leading manufacturers
- Investment and funding analysis from 2023–2025
- Product launch and approval analysis
- Competitive benchmarking matrix
The report also highlights how pharmaceutical companies are increasingly focusing on manufacturing scale expansion, strategic collaborations, licensing agreements, and geographic market penetration to strengthen their biosimilars portfolios amid rising global competition.
Key Players Profiled in the Report
The study profiles several leading companies actively operating in the biosimilars market, including:
- Sandoz Group AG
- Pfizer Inc.
- Amgen Inc.
- Celltrion Inc.
- Biocon
- Dr. Reddy’s Laboratories Ltd.
- Eli Lilly and Company
- Teva Pharmaceutical Industries Ltd.
- Fresenius Kabi AG
- STADA Arzneimittel AG
- Boehringer Ingelheim International GmbH
- Samsung Biologics
- Amneal Pharmaceuticals LLC
- Coherus BioSciences
- Bio-Thera Solutions
- Alvotech
- Shanghai Henlius Biotech, Inc.
- Polpharma Biologics Group
- Fujifilm Kyowa Kirin Biologics Co., Ltd.
The report additionally evaluates company positioning based on business strategy excellence and product portfolio strength, offering stakeholders a comprehensive view of the competitive landscape and emerging market opportunities.
Regionally, North America continues to maintain a strong market position due to established regulatory frameworks and increasing biosimilar adoption, while Asia Pacific is expected to witness notable growth driven by manufacturing expansion, cost-efficient biologics production capabilities, and increasing healthcare investments.
With growing pressure on healthcare systems to optimize biologics spending while improving treatment accessibility, biosimilars are expected to remain one of the most strategically important segments within the global biopharmaceutical industry over the next decade.
Connect with the research team for customized insights,
regional analysis, enterprise-specific requirements, or analyst consultation:
Request
Inquiry / Speak to Analyst
Explore Related Biosimilars and Biopharmaceutical Market Reports
Clinical Trial Services Market
Pharmaceutical Drug Delivery Market
Biologics Safety Testing Market
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
MarketsandMarkets™ SalesPlay is an AI-driven Revenue Intelligence Co-Pilot designed to help revenue teams prioritize the right accounts, identify critical changes early, and surface opportunities ahead of demand, so pipeline builds naturally and deals close with greater consistency.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/